About: Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults
Creator	Waghmare, Alpana Englund, Janet Gardner, Rebecca Hill, Joshua Qu, Pingping Vora, Surabhi
Source	PMC
abstract	BACKGROUND: Infectious complications of chimeric antigen receptor (CAR) T-cell immunotherapy in children and young adults have not been well described. METHODS: Medical records of patients ≤26 years old receiving CD19 CAR T-cell infusion (CTI) at a single institution between 2014 and 2017 were reviewed. The number of infections per 100 days-at-risk (infection density) in the 90 days preceding and 0–28 and 29–90 days after CTI was calculated. Poisson regression and Cox analyses were utilized to identify risk factors for infections. RESULTS: Eighty-three patients received CTI during the study period. Most patients (98%) had refractory or relapsed acute lymphoblastic leukemia (ALL). Infections occurred in 54% of patients in the 90 days before CTI (infection density, 1.23) and in 40% of patients in the first 28 days following CTI (infection density, 2.89). Infection density decreased to 0.55 in the 29–90 days post-CTI. Most infections were bacteremias (39%) or respiratory viral infections (43%). Pre-CTI risk factors associated with infection included prior hematopoietic cell transplantation (HCT), immunoglobulin G (IgG) level <400 mg/dL, and lymphodepletion other than cyclophosphamide plus fludarabine; post-CTI risk factors included higher-severity CRS and IgG <400 mg/dL. CONCLUSIONS: Infection rates in children and young adults receiving CD19 CAR T-cell therapy increase in the first month and then decline. Understanding types and timing of infections and contributing risk factors may help inform prophylactic and monitoring strategies. Specific attention should be given to patients with prior HCT, severe hypogammaglobulinemia, and severe CRS.
has issue date	2020-04-09(xsd:dateTime)
bibo:doi	10.1093/ofid/ofaa121
bibo:pmid	32432149
has license	cc-by-nc-nd
sha1sum (hex)	8c248b7ecd86825a3926cd16c51e89bcc7d63aaf
schema:url	https://doi.org/10.1093/ofid/ofaa121
resource representing a document's title	Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults
has PubMed Central identifier	PMC7221263
has PubMed identifier	32432149
schema:publication	Open Forum Infect Dis
resource representing a document's body	covid:8c248b7ecd86825a3926cd16c51e89bcc7d63aaf#body_text
is schema:about of	named entity 'chronic lymphocytic leukemia' named entity 'IgG' named entity 'B-cell lymphoma' named entity 'antitumor' named entity 'CRS' named entity 'CTI' named entity 'acute lymphoblastic leukemia' named entity 'high-risk' named entity 'radiographic' named entity 'neutropenia' named entity 'CAR T-cell' named entity 'IgG' named entity '0.98' named entity 'bacteremia' named entity 'CTI' named entity 'CRS' named entity 'infection' named entity 'infection' named entity 'acute lymphoblastic leukemia' named entity 'fludarabine' named entity 'Cox proportional hazards models' named entity 'CTI' named entity 'antiviral' named entity 'single center' named entity 'infection' named entity '28 days' named entity 'medical records' named entity 'IgG' named entity 'fungal disease' named entity 'viral infections' named entity 'antiviral' named entity 'neutropenia' named entity 'CAR T cells' named entity 'CD19' named entity 'tocilizumab' named entity 'steroids' named entity 'infection' named entity 'CAR T cells' named entity 'relapse' named entity 'Seattle Children's Hospital' named entity '28 days' named entity 'CAR T-cell therapy' named entity 'cumulative incidence' named entity 'acyclovir' named entity 'supportive care' named entity 'CAR T-cell' named entity 'CTI' named entity 'CTI' named entity 'risk factors' named entity 'lymphopenia' named entity 'infection' named entity 'neutropenia' named entity 'infection' named entity 'chimeric antigen receptor' named entity 'CTI' named entity 'Pneumocystis jirovecii' named entity 'refractory disease' named entity 'acyclovir' named entity 'neutropenia' named entity 'diagnostic test' named entity 'T-cells' named entity 'CRS' named entity 'Infection' named entity 'CAR T-cell' named entity 'risk factor' named entity 'refractory' named entity 'IVIG' named entity 'infection' named entity 'CTI' named entity 'hematologic' named entity 'Infectious Diseases' named entity 'intravenous therapy' named entity 'neutropenic' named entity 'neutropenic' named entity 'aplasia' named entity 'CTI'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software